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Rare Disease Advisory Committee
• Established 2019 to advise Drug Utilization Review Board
• Multidisciplinary committee comprised of allied healthcare
professionals (physicians, PharmD, RN, PhDs) and MO HealthNet
staff
• Quarterly meetings
• Appointment based on experience researching, diagnosing, and
treating rare diseases
• Provide expert recommendations or determinations regarding access to
drugs and/or biological products for rare disease treatment

Ivacaftor/Tezacaftor/Elexacaftor
• FDA Approval: 21 October, 2019
• Indication: treatment of cystic fibrosis (CF) in patients aged 12
years and older who have at least one F508del mutation in the
CFTR gene
• Mechanism of Action:
• Ivacaftor is a CFTR potentiator
• Tezacaftor and Elexacaftor are CFTR correctors

Dose/Administration:
• 2 tablets (elexacaftor 100 mg, tezacaftor 50 mg, and ivacaftor 75 mg) in AM
• 1 tablet (ivacaftor 150 mg) in PM

• Drug Clinical Highlights:
• First CFTR modulator therapy for F508del heterozygotes (90% of CF
population)
• FDA approval based on two phase 3 clinical trials including 510 people with
CF
• First trial demonstrated an increase in ppFEV1 of 13.8% and improvements in sweat
chloride, pulmonary exacerbation rate, and BMI
• Second trial demonstrated an increase in ppFEV1 of 10%

• Warnings regarding: liver function, concomitant use of CYP3A inhibitors, and
cataracts

• Disease Clinical Highlights:
• Pathophysiology
• Epidemiology
• Genetics

• Cost:
• $310,648 per patient annually
• Estimated at $28,000,000-55,000,000 for MO HealthNet

• No therapeutic alternatives
• Guidelines:
• Initial Therapy
• Documented diagnosis of cystic fibrosis
• Genetic testing documenting F508del

• Prescribed by or in consultation with “appropriate specialist” at a CF Care Center
• Age > 12 years
• Screening tests: LFTs, Pulm Function, eye exam, no severe liver disease

• Continuation
• Annual eye exam
• LFTs every 3 months for a year then annually
• Annual documentation of improvement in measurable goal: ppFEV1, pulmonary exacerbation,
BMI

